Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00891202 · ClinicalTrials.gov registry record · Phase 3
A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease (ENGAGE)
A Phase 3 study of Gaucher Disease, Type 1, sponsored by Genzyme, a Sanofi Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 40
- Enrollment target
- 18
- Study locations
NCT00891202 is a Phase 3 study of Gaucher Disease, Type 1 that has completed, run by Genzyme, a Sanofi Company. The registered enrollment target is 40 participants, below the 54-participant average among 8 other Gaucher Disease, Type 1 trials with a reported enrollment target (26% lower). The trial reports 18 study locations across 7 states.
The verdict
NCT00891202, a Phase 3 study of Gaucher Disease, Type 1, has completed, sponsored by Genzyme, a Sanofi Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 40 participants
- Enrollment target
- 18
- Study locations
Study Summary
This Phase 3 study was designed to confirm the efficacy and safety of eliglustat tartrate (Genz-112638) in participants with Gaucher disease Type 1.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Eliglustat tartrate
Study Locations (18)
Other
- University hospital "Alexandrovska" Sofia - Sofia
- Sir Mortimer B. Davis - Jewish General Hospital - Montreal, Quebec
- Mount Sinai Hospital and the Samuel Lunenfeld Research Institute - Toronto Ontario
- Hospital de San Jose - Bogotá
- Christian Medical College Hospital - Vellore
- Rabin Medical Center, Beilinson Hospital - Petach Tikvah
- Hôtel-Dieu de France University Hospital - Beirut
- OCA Hospital - Monterrey, Nuevo Leon
- Hematology Research Center of Ministry of Healthcare of the Russian Federation - Moscow
- Institut za endokrinologiju - Belgrade
- Royal Free Hospital - London
New York
- New York University School of Medicine, Neurology Department - New York
- Mount Sinai School of Medicine - New York
California
- UCSF MS Center - San Francisco
Connecticut
- Yale University School of Medicine - New Haven
Georgia
- Emory University Medical Genetics - Decatur
Kansas
- University of Kansas Medical Center, Division of Hematology/Oncology, Dept. of Medicine - Westwood
TN
- Hopital La-Rabta - Tunis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2009-11 |
| Est. Completion | 2016-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00891202
The ClinicalTrials.gov registry entry for NCT00891202 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 54-participant average among 8 other Gaucher Disease, Type 1 trials with a reported enrollment target (26% lower). The listed sponsor is Genzyme, a Sanofi Company, which has 196 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Gaucher Disease, Type 1 appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00891202 reports 18 study locations spanning 7 distinct geographic areas - top geographies include Other, New York, California.
Frequently Asked Questions
What is clinical trial NCT00891202 about?
NCT00891202 is a clinical study titled "A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease (ENGAGE)". This Phase 3 study was designed to confirm the efficacy and safety of eliglustat tartrate (Genz-112638) in participants with Gaucher disease Type 1.
What is the current status of trial NCT00891202?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 40 participants. The study started on 2009-11. Estimated completion is 2016-01.
What conditions does trial NCT00891202 study?
This clinical trial studies the following conditions: Gaucher Disease, Type 1.
What interventions are being tested in trial NCT00891202?
The interventions under investigation include: Placebo (DRUG), Eliglustat tartrate (DRUG).
Who is sponsoring clinical trial NCT00891202?
This trial is sponsored by Genzyme, a Sanofi Company, which has 196 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00891202 being conducted?
This trial has 18 study locations across California, Connecticut, Georgia, Kansas, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gaucher Disease, Type 1
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease Who Have Reached Therapeutic Goals With Enzyme Replacement Therapy (ENCORE)
COMPLETED · Phase 3
-
An Open-Label Extension Study of GA-GCB ERT in Patients With Type 1 Gaucher Disease
COMPLETED · Phase 3
-
A Clinical Trial of PR001 (LY3884961) in Patients With Peripheral Manifestations of Gaucher Disease (PROCEED)
RECRUITING · Phase 1
-
Long Term Follow-up Study of Type-1 Gaucher Subjects Post FLT201 Dose (GALILEO-2)
ACTIVE NOT RECRUITING · Phase 1
-
Venglustat in Combination With Cerezyme in Adult Patients With Gaucher Disease Type 3 With Venglustat Monotherapy Extension
ACTIVE NOT RECRUITING · Phase 2
-
A Study of the Efficacy and Safety of Eliglustat Tartrate (Genz-112638) in Type 1 Gaucher Patients
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.